In vivo: in orthotopic xenograft model of human PC-3 prostate cancer cells, anti-S1P monoclonal Ab (Sphingomab®) inhibited intratumoral hypoxia, induced vascular remodeling and chemotherapy sensitivity. This evidence concerns the gene MBTPS1 and prostate cancer.